Xadago/safinamide, the Italian company's lead product, has received marketing authorization for the treatment of Parkinson’s disease in the EU, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories.

Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with symptoms of schizophrenia.